Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-07-16
2010-11-09
Chen, Stacy B (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S208100, C435S320100
Reexamination Certificate
active
07829683
ABSTRACT:
A method for obtaining a vaccine against the infection of an animal host by a retrovirus capable of penetrating into a host's target cell, where the target cell possesses a membrane receptor for a protein of the host, by preparing candidate vaccine agents based on a modified polypeptide having at least part of an envelope protein of the retrovirus, where the polypeptide has at least one fragment of an immunodominant region of the envelope protein, the fragment containing at least one conserved amino acid of the immunodominant region present in the pathogenic strain, wherein the polypeptide induces an immune response directed both against the immunodominant region and against the protein of the host; and selecting as a vaccine such a modified polypeptide chosen from those which induce an immune response directed against said immunodominant region of the envelope protein and not against the protein of the host.
REFERENCES:
patent: 6017536 (2000-01-01), Barney et al.
patent: 6824783 (2004-11-01), Bolognesi et al.
patent: WO 93 01304 (1993-01-01), None
patent: WO 94 02505 (1994-02-01), None
patent: WO 94 06471 (1994-03-01), None
Zandman-Goddard and Shoenfeld, Autoimmunity Reviews, 2002, 1:329-337.
R. P. Johnson et al., “Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation,”Journal of Experimental Medicine, Apr. 1, 1992, 175(4) pp. 961-971.
Fahey et al., “Status of immune-based therapies in HIV infection and AIDS,”Clin. Exp. Immunol., vol. 88, pp. 1-5, 1992.
Fox, J. “No winners against AIDS,”Bio/Technology, vol. 12, p. 128, 1994.
Haynes et al., “Update on the Issues of HIV Vaccine Development,”The Finnish Medical Society DUODECIM, Ann Med, vol. 28, pp. 39-41, 1996.
Reiher, Walter E., III, et al., “Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 9188-9192, Dec. 1986.
Bost, K. L., et al., “Individuals infected with HIV possess antibodies against IL-2,” Immunology, vol. 65, pp. 611-615, 1988.
Levy, Jay A., “Pathogenesis of Human Immunodeficiency Virus Infection,” Microbiological Reviews, vol. 57, No. 1, pp. 183-289, Mar. 1993.
Steuler et al. “Distinct Populations of Human Immunodeficiency Virus Type 1 in Blood and Cerebrospinal Fluid,” AIDS Research and Human Retroviruses, 1992, 8(1):53-59.
Chen Stacy B
Lomastar Technologies Sarl
Oliff & Berridg,e PLC
LandOfFree
Polynucleotides encoding modified HIV-1 gp41 membrane... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding modified HIV-1 gp41 membrane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding modified HIV-1 gp41 membrane... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173487